x

75% of people globally want unbiased news (Pew Research) but are concerned they're not getting that.

Get balanced coverage with Symby. See how stories are covered across diverse outlets and spot when one side covers a story the other skips.

PODCAST

Biotech Hangout

Daphne Zohar, Josh Schimmer, Brad Loncar, Tim Opler & more

A weekly discussion of all things biotech – breaking news, data, deals, and FDA actions – with a community of biotech industry leaders and experts. Join the live streams hosted by @BiotechCH, @daphnezohar, @bradloncar and @biotech1 on Twitter Spaces every Friday at 12pm ET.

science life sciences

All Episodes

01:00:10

Episode 129 - January 31, 2025

Biotech Hangout ·

2025/02/23

On this week’s episode, Brad Loncar, Chris Garabedian, Eric Schmidt, Paul Matteis and Sam Fazeli kick off with an open mic session on the potential impact of the RFK Jr. hearings and the Trump administration's policies on the biotech industry. The conversation turns to a “unicorn day” with IPOs for Metsara, Maze, Odyssey and Sionna Therapeutics. The group also discusses the approval of Vertex’s journavx and the potential for it to be a blockbuster drug. Akero, Sarepta and Cargo also announced

en

01:00:52

Episode 128 - January 24, 2025

Biotech Hangout ·

2025/02/23

On this week’s episode, Chris Garabedian, Tim Opler, Sam Fazeli, Brian Skorney and Luba Greenwood begin with breaking news on the obesity front with Novo Nordisk’s next-gen program, amycretin. The conversation transitions to post-JPM public market sentiment and a reluctance in capital markets. On the flip side, the hosts suggest a positive outlook for venture capital investments despite the public market challenges. The group also highlights the active M&A and licensing deal market, including

en

00:57:32

Episode 127 - January 17, 2025

Biotech Hangout ·

2025/02/23

On this week’s episode, Daphne Zohar, John Maraganore, Mike Yee and Sam Fazeli begin the show recapping JPM ’25, noting investor sentiment was muted and concerns on interest rates have contributed to mixed market sentiment. In terms of deals, three M&A transactions were announced this week including J&J’s plans to buy Intra-Cellular Therapies for $14B, Gilead’s $250M preclinical asset acquisition and GSK’s $1.2B deal with IDRx. Commenting on a challenging IPO market, the group discusses

en

00:58:49

Episode 126 - January 10, 2025

Biotech Hangout ·

2025/02/23

On this week’s episode, hosts Chris Garabedian, Brad Loncar,Sam Fazeli and Yaron Werber cover a busy news week ahead of the J.P. Morgan Healthcare Conference as well as a preview of what to expect next week at the event. Thegroup highlights some of the mega private deals announced, including three that involved the licensing of China assets. The hosts zoom out with a recap of end-of-year reports, the current state of the market and XBI outlook. On the data front, Jasper reports positive Phase 1/2

en

00:59:15

Episode 125 - December 20, 2024

Biotech Hangout ·

2025/02/23

On this week’s episode, Brad Loncar, Daphne Zohar, Josh Schimmer, Yaron Werber and Michael Preminger kick off the show with Vertex’s much anticipated Phase 2 study results, highlighting the modest treatment effect and high placebo response. The group also comments on overly positive spin on data and the importance of credibility in interpreting data. The conversation turns to Novo Nordisk’s weight loss data and the market’s negative reaction with stock down 20%. The group also discusses Roche’s

en

00:59:41

Episode 124 - December 13, 2024

Biotech Hangout ·

2025/02/23

On this week’s episode, Josh Schimmer, Yaron Werber, Brian Skorney, Tess Cameron, and Eric Schmidt kick off the show covering the macro news of the week including the new FTC head and what it means for M&A in the industry. The group also discusses how the biopharma industry is not challenging RFK Jr., the BioSecure Act missing from the Defense Bill and Luigi Mangione’s arrest. In ASH Conference highlights, the hosts recap the CAR-T battle of Arcellx/Gilead vs Ligand/J&J, as well as updates

en

01:00:07

Episode 122 - November 22, 2024

Biotech Hangout ·

2025/02/23

On this episode of Biotech Hangout, Eric Schmidt, Bruce Booth, Yaron Werber, Tim Opler and Mike Yee begin the show discussing the highlights from the Jefferies Healthcare Conference before taking a look at public investor sentiment this week. The discussion turns to Atlas Venture’s 2024 Year in Review and transitions into the emerging themes for 2025. The hosts also recap ACR Convergence including Amgen’s Phase 3 data as well as data from cell therapies for SLE, SSC, IMNM. The group also discuss

en

01:00:51

Episode 121 - November 15, 2024

Biotech Hangout ·

2025/02/23

On this episode, Brad Loncar, Sam Fazeli, Tess Cameron, Nina Kjellson and Michal Preminger kick off the show sharing perspectives on Trump’s selection of Robert F. Kennedy Jr as secretary of the U.S. Department of Health and Human Services. The hosts shift to Abbvie’s disappointing Phase 2 trials and a broader discussion on why M&A can be tough. The group also discussed the recent flood of licensing and new companies based on China assets, including some of the players and approaches. The hosts

en

00:59:53

Episode 120 - November 8, 2024

Biotech Hangout ·

2025/02/23

On this episode, Daphne Zohar, John Maraganore, Josh Schimmer, Eric Schmidt and Sam Fazeli are joined by Endpoints’ Zach Brennan for a discussion on the election results and what we can expect with a Trump administration, including the negatives/risks for the biotech industry as well as the positives and potential opportunities. The hosts also cover other news from the week including Moderna’s Q3 earnings and the company’s CEO Bancel stepping down as sales chief, as well as BioNTech’s Q3 earnings

en

00:58:49

January 10, 2025

Biotech Hangout ·

2025/02/07

On this week’s episode, hosts Chris Garabedian, Brad Loncar,Sam Fazeli and Yaron Werber cover a busy news week ahead of the J.P. Morgan Healthcare Conference as well as a preview of what to expect next week at the event. Thegroup highlights some of the mega private deals announced, including three that involved the licensing of China assets. The hosts zoom out with a recap of end-of-year reports, the current state of the market and XBI outlook. On the data front, Jasper reports positive Phase 1/2

en

01:01:28

Episode 118

Biotech Hangout ·

2024/10/30

On this episode of Biotech Hangout, hosts Chris Garabedian, Daphne Zohar, Josh Schimmer, Tim Opler, Paul Matteis and special guest Allison DeAngelis kick off the show with a look at the renewed interest and recent funding in the neuropsychiatric disease space, including Seaport Therapeutics’ $225 million Series B financing. This progresses into a comparison of diversified versus focused pipelines as Roivant CEO Matt Gline joins the stage as an impromptu guest to share his perspective on the benefits

en

00:58:19

Episode 117

Biotech Hangout ·

2024/10/30

On this week’s episode of Biotech Hangout, hosts DaphneZohar, Josh Schimmer, Brad Loncar, John Maraganore, Paul Matteis, Mike Yee and Tess Cameron open up with market commentary and how derivatives, debates and dynamics are impacting stocks including Scholar Rock, Biohaven, Roche and Regeneron. The group also highlights CeriBell, which is the first medtech IPO in years. The hosts turn to neuro sentiment with a look at Lundbeck’s acquisition of Longboard at an approximate value of $2.5 billion net

en

00:59:50

Episode 116

Biotech Hangout ·

2024/10/30

On this week’s episode of Biotech Hangout, hosts Chris Garabedian, Bruce Booth, Josh Schimmer, Eric Schmidt and Sam Fazeli start the show on the topic of M&A and ponder “where are the deals?” as they consider potential reasons such as the U.S. election, too few assets or too few buyers. The conversation turns to the venture funding environment with a preview of the third quarter venture funding numbers. On the theme of stock price reactions, the group digs into why Sarepta’s has dropped despite

en

00:59:56

Episode 115

Biotech Hangout ·

2024/10/30

On this week’s Biotech Hangout, hosts Josh Schimmer, Brad Loncar, Sam Fazeli and Tess Cameron kick off the show digging into some macro trends and the potential of an incoming M&A wave. The conversation then turns to a range of topics related to China, including the impact of the stimulus, recent innovation, and the latest obesity assets & China-sourced drugs. The hosts also discuss the updates coming out of Roche’s business day, including the company’s acquisition of a CDK inhibitor from

en

01:00:06

Episode 14

Biotech Hangout ·

2024/09/25

On this week’s Biotech Hangout, hosts Daphne Zohar, Brad Loncar, Josh Schimmer, Chris Garabedian, John Maraganore and Sam Fazeli kick off the show sharing perspectives on the markets and its effects on the growing queue of biotech IPOs, particularly following the influx of large private deals over the past few months. As the founding CEO of Alnylam, John provides his thoughts on the Helios-B full study data presentation at the ESC Congress while the broader group weighs in on the competitive

en

00:59:50

Episode 113

Biotech Hangout ·

2024/08/27

On this week’s Biotech Hangout, hosts Brad Loncar, Tim Opler, Josh Schimmer and Sam Fazeli assess the recent macro trends, including the current state of the US economy and some good news for biotech. The group also discussed the big reveal this week on Medicare drug pricing issues and industry perspectives on whether it was more of a whimper versus a bang. In M&A, the Revance and Crown Laboratories merger was discussed as well as broader M&A trends including how a potential change in the

en

01:00:37

Episode 112

Biotech Hangout ·

2024/08/19

On this week’s Biotech Hangout, hosts Eric Schmidt, Brad Loncar, Brad Skorney, Luba Greenwood and Josh Schimmer kick off the episode summarizing the wild week for biotech stocks. The group also recaps some of the big earning announcements from the week, including a larger discussion on overall learnings from the Q2 earnings season. The hosts discuss Charles River Laboratories as a harbinger of pharma cost cutting and share general perspectives on the IRA impact on pharma. The FDA’s approval of

en

01:01:04

Episode 110

Biotech Hangout ·

2024/08/02

On this week’s episode, hosts Josh Schimmer, Sam Fazeli, Brian Skorney, Michal Preminger and Eric Schmidt kick off the show by discussing the recent growth in XBI performance. The group weighs in on IPO dynamics, hypothesizing on the influence of investors and the power of FOMO. They go on to note the success of Viking Therapeutics as they’re moving into Phase 3 for their GLP-1 agonist, and what the future may hold for the weight-loss drug market. Shifting gears, the hosts raise concerns on CHMP

en

01:03:23

Episode 109

Biotech Hangout ·

2024/07/24

On this week’s episode, hosts Daphne Zohar, Josh Schimmer, Sam Fazeli, Luba Greenwood, Brian Skorney and Paul Matteis begin the show with commentary on the Republican National Convention, including former President Trump’s pick of former biotech entrepreneur and Senator J.D. Vance as his running mate and the potential impact of this administration on the biotech sector, if elected. The discussion transitions to the week’s theme of biotech catalysts, including stock reactions in the current

en

01:00:13

Episode 108

Biotech Hangout ·

2024/07/23

On this week’s episode, hosts Chris Garabedian, Brad Loncar, Tim Opler, Dawn Bell, John Maraganore and Eric Schmidt provide a deep dive into the obesity, diabetes and cardiometabolic space, beginning with an overview of the key findings in Stifel’s latest obesity report. The hosts also provide a recap of ADA and EASD abstract highlights and take a look at the next wave of injectable therapies and the trends in consumerization and access. They also discuss Pfizer’s update on its once daily oral

en

139 results

Similar Podcasts

Classic Radio Science Fiction

solgoodmedia.com

Mission to Mars

Inception Point Ai

The 365 Days of Astronomy

365DaysOfAstronomy.org

Creek Devil

william Jevning

UFO Chronicles Podcast

Nik Hunter